Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma

Completed · Not applicable

Conditions studied: Glioma, Glioblastoma

In brief

It was previously shown that 18F-DOPA PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been demonstrated. Regulatory agencies require randomized trials to determine the impact of PET on patient management and outcome. In this study we hypothesize that the addition of 18F-DOPA PET will improve patient outcome by more accurately identifying presence or absence of tumor recurrence than conventional imaging.

Key facts

Study ID

NCT01813877

Run by

Jonsson Comprehensive Cancer Center

People needed

37

Starts

2012-08-22

Expected to finish

2020-01-14

Last updated by the study team

2020-07-27

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Suspected first recurrence of a glioblastoma tumor by clinical measures and/or MRI
• Age 18-99 years

You may not qualify if…

• Breast feeding/ Pregnancy
• Severe psychiatric illness
• Primary diagnosis of a glioblastoma

Where it is running

• UCLA — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.